Drug intelligence / Profile preview

CNP-105

Development stage: Unknown
Lead developer: COUR Pharmaceuticals
Modality: Nanoparticles → Drug Delivery Systems
Administration: Intravenous

Overview

CNP-105 is a drug candidate developed by COUR Pharmaceuticals, in partnership with Ironwood Pharmaceuticals, for the treatment of Primary Biliary Cholangitis (PBC). It utilizes COUR's proprietary nanoparticle platform to induce antigen-specific tolerance to liver autoantigens, aiming to modulate the immune response responsible for the disease. The program advanced into a Phase 2 partnered program following COUR's 2022 financing.

Beyond the preview

Go deeper on CNP-105.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CNP-105.

Explore the full profile